Harvard Bioscience, Inc. (NASDAQ:HBIO) Director George Uveges sold 35,054 shares of the stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $4.61, for a total value of $161,598.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) opened at $4.80 on Tuesday. The company has a current ratio of 3.40, a quick ratio of 1.87 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $160.45, a price-to-earnings ratio of 76.67 and a beta of 1.32. Harvard Bioscience, Inc. has a twelve month low of $2.25 and a twelve month high of $5.20.
Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, March 1st. The medical instruments supplier reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. The company had revenue of $27.46 million during the quarter, compared to analyst estimates of $26.60 million. Harvard Bioscience had a positive return on equity of 2.38% and a negative net margin of 0.85%. equities analysts forecast that Harvard Bioscience, Inc. will post 0.11 EPS for the current year.
A number of institutional investors have recently bought and sold shares of HBIO. Granahan Investment Management Inc. MA lifted its holdings in Harvard Bioscience by 80.7% during the third quarter. Granahan Investment Management Inc. MA now owns 537,467 shares of the medical instruments supplier’s stock worth $2,016,000 after buying an additional 240,055 shares during the period. New York State Common Retirement Fund purchased a new stake in Harvard Bioscience during the third quarter worth $321,000. Dimensional Fund Advisors LP lifted its holdings in Harvard Bioscience by 4.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,710,722 shares of the medical instruments supplier’s stock worth $4,362,000 after buying an additional 79,374 shares during the period. Segall Bryant & Hamill LLC lifted its holdings in Harvard Bioscience by 9.8% during the fourth quarter. Segall Bryant & Hamill LLC now owns 836,318 shares of the medical instruments supplier’s stock worth $2,760,000 after buying an additional 74,307 shares during the period. Finally, Algert Global LLC lifted its holdings in Harvard Bioscience by 25.7% during the fourth quarter. Algert Global LLC now owns 187,422 shares of the medical instruments supplier’s stock worth $618,000 after buying an additional 38,328 shares during the period. Institutional investors own 63.54% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/03/13/harvard-bioscience-inc-hbio-director-sells-161598-94-in-stock.html.
About Harvard Bioscience
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.